Inhaled Nitric Oxide Testing in Predicting Prognosis in Pulmonary Hypertension Due to Left-Sided Heart Diseases
ESC Heart Failure · 2023
DOI: 10.1002/ehf2.14515 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Taijyu Satoh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Heart Failure. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Aims
The pathophysiology of pulmonary hypertension (PH) due to left-sided heart disease (Group 2 PH) is distinct from that of other groups of PH, yet there are still no approved therapies that selectively target pulmonary circulation. The increase in pulmonary capillary pressure due to left-sided heart disease is a trigger event for physical and biological alterations of the pulmonary circulation, including the nitric oxide (NO)–soluble guanylate cyclase–cyclic guanosine monophosphate axis. This study investigated inhaled NO vasoreactivity tests for patients with Group 2 PH and hypothesized that these changes may have a prognostic impact. Methods and results This was a single-centre, retrospective study with a median follow-up of 365 days. From January 2011 to December 2015, we studied 69 patients with Group 2 PH [age, 61.5 ± 13.0 (standard deviation) years; male:female, 49:20; left ventricular ejection fraction, 50.1 ± 20.4%; mean pulmonary arterial pressure, ≥25 mmHg; and pulmonary arterial wedge pressure (PAWP), >15 mmHg]. No adverse events were observed after NO inhalation. Thirty-four patients with Group 2 PH showed increased PAWP (ΔPAWP: 3.26 ± 2.22 mmHg), while the remaining 35 patients did not (ΔPAWP: −2.11 ± 2.29 mmHg). Multivariate analysis revealed that increased PAWP was the only significant predictor of all-cause death or hospitalization for heart failure (HF) after 1 year (hazard ratio 4.35; 95% confidence interval, 1.27–14.83; P = 0.019). The acute response of PAWP to NO differed between HF with preserved and reduced ejection fractions.
Conclusions
Patients with Group 2 PH were tolerant of the inhaled NO test. NO-induced PAWP is a novel prognostic indicator.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Cardiovascular Advanced Medicine in Pulmonary Hypertension, National Cerebral and Cardiovascular Center, Suita, Japan.
- Department of Cardiology, International University of Health and Welfare, Otawara, Japan.
- Teikyo University Graduate School of Public Health, Tokyo, Japan.
ORCID-Profile: Taijyu Satoh
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Satoh, T., Yaoita, N., Nochioka, K., Tatebe, S., Hayashi, H., Yamamoto, S., Sato, H., Takahama, H., Suzuki, H., Terui, Y., Yamada, K., Yamada, Y., Inoue, T., Aoki, T., Satoh, K., Sugimura, K., Miyata, S., & Yasuda, S. (2023). Inhaled Nitric Oxide Testing in Predicting Prognosis in Pulmonary Hypertension Due to Left-Sided Heart Diseases. ESC Heart Failure. https://doi.org/10.1002/ehf2.14515
Vancouver
Satoh T, Yaoita N, Nochioka K, Tatebe S, Hayashi H, Yamamoto S, et al. Inhaled Nitric Oxide Testing in Predicting Prognosis in Pulmonary Hypertension Due to Left-Sided Heart Diseases. ESC Heart Failure. 2023. doi:10.1002/ehf2.14515
BibTeX
@article{Satoh2023,
author = {Satoh, Taijyu and Yaoita, Nobuhiro and Nochioka, Kotaro and Tatebe, Shunsuke and Hayashi, Hideka and Yamamoto, Saori and Sato, Haruka and Takahama, Hiroyuki and Suzuki, Hideaki and Terui, Yosuke and Yamada, Kaito and Yamada, Yusuke and Inoue, Takumi and Aoki, Tatsuo and Satoh, Kimio and Sugimura, Koichiro and Miyata, Satoshi and Yasuda, Satoshi},
title = {Inhaled Nitric Oxide Testing in Predicting Prognosis in Pulmonary Hypertension Due to Left-Sided Heart Diseases},
journal = {ESC Heart Failure},
year = {2023},
doi = {10.1002/ehf2.14515}
}
EUVIMED